

2010-10-20
新光吳火獅紀念醫院急診醫學部

ER-Infection Combined Conference

報告者：和信內科部 PGY 黃振洋
指導者：VS 洪世文

Discussion

- Fever of Unknown origin (FUO)
- Febrile neutropenia (Neutropenic fever)
- When FUO meets neutropenia

Fever of unknown origin

- Fever of unknown origin
 - Definition
 - Fever > 38.3°C
 - Duration > 3 weeks or > 1 weeks after inpatient investigation

TABLE 18-3 Categories of FUO


Feature	Recurrent	Neutropenic	HIV-Associated	Classic
Patient's situation	Hospitalized, acute care, no infection when admitted	Neutrophil count either <500/ μ L or expected to reach that level in 1-2 days	Confirmed HIV-positive	All others with fevers for ≥ 3 weeks
Duration of illness while under investigation	3 days*	3 days*	3 days* (or 4 weeks as outpatient)	3 days* or three outpatient visits
Examples of cause	Septic thrombophlebitis, sinusitis, Clostridium difficile colitis, drug fever	Perianal infection, aspergillosis, candidemia	MAR infection, tuberculosis, non-Hodgkin's lymphoma, drug fever	Infections, malignancy, inflammatory disorders, drug fever

Fever of unknown origin

TABLE 18-3 Ten Leading Causes of Classic FUO among Adults at Community Hospitals in the United States

Cause	% of Total
Lymphoma	16
Collagen vascular disease	16
Abscess	13
Undiagnosed cause	9
Solid tumor	8
Thrombosis or hematoma	7
Granulomatous disease, nonmycobacterial	5
Endocarditis	5
Mycobacterial disease	5
Viral disease	5
Remaining causes	11
	100

Fever of unknown origin



Febrile neutropenia

- Febrile neutropenia (Neutropenic fever)
- Definition (IDSA 2002 guideline):
 - Fever > 38.3°C or fever > 38°C for 1 hour
 - ANC < 500 cells/ml or ANC < 1000 with a predicted decrease to < 500 cells/ml
- Fever can be the only infectious signs in patients with neutropenia
 - Febrile reaction involved neutrophils, endothelium, lymphocyte, macrophage...
 - Notably bacterial infection (especially Gram negative)
 - Common infection sites: **lungs (25%)**; mouth and pharynx (25%); soft tissue; skin and CVC (15%); perineum (10%); GI/GU tract (5%) and the nose/sinuses (5%)

Febrile neutropenia


• Pathogens:

- Gram-negative in 80% of cases, gram-positive in 60% of cases
- E. coli (29%), Pseudomonas aeruginosa (18%), Klebsiella sp (16%)

Table 3. Medical complications in 72 febrile neutropenic patients with bacteremia due to a single pathogen, according to pathogen and Multinational Association for Supportive Care in Cancer (MASCC) score.

Outcome	No. (%) of patients, by class of pathogen and risk group			
	Gram-negative		Gram-positive	
	Low risk (n = 13)	High risk (n = 20)	Low risk (n = 26)	High risk (n = 13)
Resolution				
Without complications	11 (85)	5 (25)	20 (77)	9 (69)
With complications	2 (15)	6 (30)	5 (19)	4 (31)
Death	0	9 (45)	1 (4)	0

Febrile neutropenia



Cheng Deh-lin et al. Guideline for the use of antimicrobial agents in patients with febrile neutropenia in Taiwan. J Microbiol Immunol Infect 2005;38:455-457

Febrile neutropenia

Table 3. Factors that favor a low risk for severe infection among patients with neutropenia.

Absolute neutrophil count of ≥ 100 cells/mm³
 Absolute monocyte count of ≥ 100 cells/mm³
 Normal findings on a chest radiograph
 Nearly normal results of hepatic and renal function tests
 Duration of neutropenia of < 7 days
 Resolution of neutropenia expected in < 10 days
 No intravenous catheter-site infection
 Early evidence of bone marrow recovery
 Malignancy in remission
 Peak temperature of $< 39.0^\circ\text{C}$
 No neurological or mental changes
 No appearance of illness
 No abdominal pain
 No comorbidity complications^a

Table 1. Scoring system for risk of complications among febrile neutropenic patients, based on the Multinational Association for Supportive Care in Cancer predictive model [6].

Characteristic	Point score
Burden of illness	
No or mild symptoms	5
Moderate symptoms	3
No hypotension	5
No chronic obstructive pulmonary disease	4
Solid tumor or no previous fungal infection in hematologic tumor	4
Outpatient status	3
No dehydration	2
Aged < 60 years	2
Score > 21 : low risk	

Febrile neutropenia

- G-CSF administration
 - shorten the duration of neutropenia, but not morbidity
 - Not routinely recommended for uncomplicated patients
- Granulocyte transfusion +/- dexamethasone
 - No evidence of efficacy
 - use with caution of toxicities (CMV infection, fever, GVHD...)

When FUO meets Neutropenia...

- Benign presentation?
 - 49% low risk group vs. 35% high risk group
 - Lack of evidence of localized infection
 - But higher mortality rate if FUO not respond to initial antibiotics treatment
- Repeated physical exam and history taking is needed
- Laboratory exam
 - CRP vs procalcitonin?
 - Procalcitonin level associated with systemic bacterial infection and response to antibiotics

When FUO meets Neutropenia...




Fig. 2. Re-evaluation of the patient with febrile neutropenia during the episode. BG, β-D-glucan; CM, colistin methanesulfonate; PCR, polymerase chain reaction.

When FUO meets Neutropenia...



- Neutropenia with no known chemotherapy or irradiation?
 - Causes other than infection are needed to be found

Take home message



- Fever of unknown origin
 - Definition
 - Differential diagnosis
- Febrile neutropenia
 - Definition
 - Management: empiric antibiotics
- Detailed history taking and physical exams

Thanks for your attention!



Reference:

1. Harrison's internal medicine, 17th edition
2. Hughes et al. 2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer. Clinical Infectious Diseases 2002; 34:730–51
3. Cheng Deh-lin et al. Guideline for the use of antimicrobial agents in patients with febrile neutropenia in Taiwan. J Microbiol Immunol Infect 2005;38:455-457
4. Anastasia Antoniadou MD et al. Fever of Unknown Origin in Febrile Leukopenia. Infect Dis Clin N Am 21 (2007) 1055–1090
5. Jean Klastersky. Management of Fever in Neutropenic Patients with Different Risks of Complications. Clinical Infectious Diseases 2004; 39:S32–7

